GBP1 and lung adenocarcinoma: (e) Fifthly, the median of follow‐up duration was 56 months (range: 2 months‐96 months), and longer follow‐up period was needed for further validating the long‐term clinical role of GBP1 in the management of lung adenocarcinoma.